Cargando…
Tularemia vaccine development: paralysis or progress?
Francisella tularensis (Ft) is a gram-negative intercellular pathogen and category A biothreat agent. However, despite 15 years of strong government investment and intense research focused on the development of a US Food and Drug Administration-approved vaccine against Ft, the primary goal remains e...
Autores principales: | Sunagar, Raju, Kumar, Sudeep, Franz, Brian J, Gosselin, Edmund J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869881/ https://www.ncbi.nlm.nih.gov/pubmed/27200274 http://dx.doi.org/10.2147/VDT.S85545 |
Ejemplares similares
-
Preclinical Testing of a Vaccine Candidate against Tularemia
por: Suresh, Ragavan Varadharajan, et al.
Publicado: (2015) -
Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants
por: Kumar, Sudeep, et al.
Publicado: (2019) -
Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine against Pulmonary Pneumococcal Infection
por: Kumar, Sudeep, et al.
Publicado: (2020) -
Evaluation of an outbred mouse model for Francisella tularensis vaccine development and testing
por: Sunagar, Raju, et al.
Publicado: (2018) -
Downmodulation of Vaccine-Induced Immunity and Protection against the Intracellular Bacterium Francisella tularensis by the Inhibitory Receptor FcγRIIB
por: Franz, Brian J., et al.
Publicado: (2015)